Title : Data analysis on the use of PCSK9 inhibitor (evolocumab – 140 mg/ml administered subcutaneously twice a month) in high cardiovascular risk patients with acute coronary syndrome undergoing coronary artery bypass grafting: A retrospective registry data analysis from January 2022 To July 2023
Abstract:
This presentation will discuss a retrospective analysis of the impact of administering the PCSK9 inhibitor evolocumab (140 mg/ml, subcutaneously twice a month) in addition to standard therapy (statins + ezetimibe) on LDL cholesterol levels and major adverse cardiovascular events (MACE) in high-risk patients with acute coronary syndrome (ACS) undergoing coronary artery bypass grafting (CABG). The study evaluates data from January 2022 to July 2023 and compares outcomes with a control group treated only with statins + ezetimibe. Key endpoints include preoperative and postoperative total cholesterol and LDL levels, as well as the incidence of MACE at discharge, 1 month, and 3 months post-CABG. The results aim to elucidate the effectiveness of PCSK9 inhibitors in rapidly achieving target cholesterol levels and reducing cardiovascular events in this critical patient population.
Audience Take Away:
- Understanding the efficacy of evolocumab combined with standard therapy in reducing LDL levels and MACE in high-risk ACS patients undergoing CABG
- Insights into how rapid cholesterol management can improve post-surgical outcomes in cardiovascular patients
- Implications for future therapeutic guidelines and potential expansion of research into PCSK9 inhibitors’ benefits in similar patient cohorts
- Practical strategies for incorporating PCSK9 inhibitors into treatment plans for high-risk cardiovascular patients to optimize outcomes
•
New data supporting the importance of aggressive and timely cholesterol management in critical care settings.
